Johnson & Johnson http://www.jnj.com/
Robert Wood Johnson concluded there ought to be a better way. Mr. Johnson joined with his two brothers, James Wood and Edward Mead Johnson, who had formed a partnership in 1885. Operations began in New Brunswick, New Jersey, in 1886 with 14 employees on the fourth floor of a small building that once was a wallpaper factory. In 1887 the Company was incorporated as Johnson & Johnson.
Johnson & Johnson went from a privately-held company to one publicly traded on the New York Stock Exchange in 1944.
In 1982 and again in 1986 TYLENOL®, a product of our McNeil Consumer & Specialty Pharmaceuticals subsidiary, was altered by unknown individuals who placed deadly cyanide in the capsule form of the product. The result was the death of seven people in 1982. The product was voluntarily recalled and Johnson & Johnson took a $100 million charge against earnings.
日本経済新聞 2006/6/27
ファイザーから大衆薬事業買収 J&Jが発表
米医薬品・健康関連大手のジョンソン・エンド・ジョンソン(Ｊ＆Ｊ)は２６日、同業のファイザーから大衆薬事業を買収すると正式発表した。買収額は１６６億ドル(約１兆９３００億円）。Ｊ＆Ｊは同事業で世界シェアトップで、ファイザーからの事業買収により同部門を一段と拡大する。
ファイザー側は中核の医療用医薬品に経営資源を集中させる狙い。売却益は自社株購入に充てる。
Ｊ＆Ｊは売り上げが伸び悩んでおり、買収・合併による拡大を模索していた。口腔洗浄剤「リステリン」や禁煙補助剤「ニコレット」など有力商品を持つファイザーの大衆薬事業を手に入れることでテコ入れする。
2006/6/26 Johnson
& Johnson Pfizer発表 Pfizer方針
Johnson &
Johnson to Acquire Pfizer Consumer Healthcare; Combination
Creates World's Premier Consumer Health Care Company
All Cash Transaction is Valued at $16.6 Billion
http://www.jnj.com/news/jnj_news/20060625_220255.htm
Johnson & Johnson,
the world's most comprehensive and broadly based manufacturer of
health care products, today announced that it has entered into a
definitive agreement to acquire Pfizer Consumer
Healthcare
for $16.6
billion in cash.
The Johnson & Johnson Board of Directors has given approval
to the transaction. Closing is subject to customary clearances,
including the Hart-Scott-Rodino Antitrust
Improvements Act
and European Union merger control regulation. The transaction is
expected to close by the end of 2006.
The Pfizer Consumer Healthcare business adds a diverse portfolio
of strong, growing, enduring brands that provide Johnson &
Johnson with leadership positions in nine
additional categories, including large new segments such as
smoking cessation and mouthwash.
The combined portfolio of OTC brands will solidify the global
market-leading position of Johnson & Johnson's OTC franchise.
Under the terms of the agreement, Johnson & Johnson will also
acquire the U.S. OTC switch rights to ZYRTEC - Pfizer's once-a-day,
non-sedating prescription antihistamine抗ヒスタミン剤, upon patent expiration.
Pfizer Reaches Agreement to Sell Its Consumer Healthcare Business to Johnson & Johnson for $16.6 Billion
http://mediaroom.pfizer.com/index.php?s=press_releases&item=73
・ Company Will Use After-Tax Proceeds to Invest in New Products and Innovative Technologies and Enhance Shareholder Returns ・ Pfizer Now Expects to Purchase up to $17 Billion in Stock in 2006-7 ・ CEO McKinnell: 'We Have Taken Another Important Step to Create Value for Our Shareholders While Transforming Our Company' ・ Consumer Healthcare Colleagues 'Have Done a Superb Job in Building an Outstanding Business' Pfizer Inc said today that it has reached a definitive agreement to sell its Pfizer Consumer Healthcare (PCH) business to Johnson & Johnson for $16.6 billion in cash, resulting in about $13.5 billion in after-tax proceeds.
The agreement, approved by the Pfizer Board of Directors, completes a review of strategic options for the consumer business that Pfizer initiated in February.
Hart-Scott-Rodino Antitrust Improvements Actの概要
HSR法は、一定の要件を満たす資産および議決権付株式の取得に適用。HSR法は手続法。同法は、事前届出制度と待機期間を規定。
現行のHSR法上の取引規模要件は、5,000万ドル。
HSR法による「当事者規模」要件は、一般に、取引の一方当事者が1億ドル以上の資産又は売上を有し、他方当事者が1,000万ドル以上の資産又は売上を有する場合。